<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31639">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01723618</url>
  </required_header>
  <id_info>
    <org_study_id>Cardoz-005</org_study_id>
    <nct_id>NCT01723618</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of CRD007 in Patients With Abdominal Aorta Aneurisms.</brief_title>
  <official_title>An Open-label, Randomised, Uncontrolled Trial Investigating the Pharmacokinetics of CRD007 After Single Dose Administration to Subjects With Abdominal Aortic Aneurysm (AAA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardoz AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardoz AB</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the plasma levels of CRD007 in patients with
      abdominal aortic aneurysms after the administration of single doses of tablets containing
      10, 25 and 40 mg CRD007.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics - maximum plasma concentration (Cmax)</measure>
    <time_frame>Pre-dose and until 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as Cmax will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - time to maximum plasma concentration (tmax)</measure>
    <time_frame>Pre-dose til 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as tmax will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Area under the plasma concentration curve (AUC)</measure>
    <time_frame>Pre-dose until 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as AUC will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - elimination half life (t1/2)</measure>
    <time_frame>pre-dose until 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as t1/2 will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose linearity</measure>
    <time_frame>Pre-dose and until 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of dose linearity in the dose range 10 - 40 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential for accumulation</measure>
    <time_frame>Pre-dose untill 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>To estimate the accumulation of CRD007 in the dose range 10 - 40 mg</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Abdominal Aortic Aneurisms</condition>
  <arm_group>
    <arm_group_label>CRD007 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRD007, 10 mg tablet, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRD007  25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRD007, 25 mg tablet, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRD007 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRD007, 40 mg tablet, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRD007</intervention_name>
    <arm_group_label>CRD007 10 mg</arm_group_label>
    <arm_group_label>CRD007  25 mg</arm_group_label>
    <arm_group_label>CRD007 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infra-renal abdominal aortic aneurysm

        Exclusion Criteria:

          -  Significant concurrent disease or medical conditions that are deemed to interfere
             with the pharmacokinetics or the safety of CRD007 conduct of the trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikolaj F Groendal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Vascular Surgery  Viborg Hospital Heiberg All√© 4 DK-8800 Viborg Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Vascular Surgery Viborg Hospital</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 28, 2012</lastchanged_date>
  <firstreceived_date>November 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
